Gyre Therapeutics Inc.: Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Fri, 7 August 2026
What it is about
Richtung AllzeithochKorrektur FahrtChuck PadalaGlobenewswire EuropeThomas EastlingYue XiongGyre PharmaceuticalsDevelopment ExpenseAstellas Pharma IncPipeline Development UpdatesChina National Medical Products AdministrationUnited StatesExchange CommissionCompany NasdaqGroup LtdCullgen IncPing Zhang, Guangdong, ChinaBeijing, Beijing, ChinaChinaSan Diego, California, United States
Who published it, and when
How it spread - 1 original report
Fri, 7 August 2026
1 report- finanznachrichten.de13:06first to report
Q2 2026 revenue of $29.1 million; GAAP basic EPS: $(0.12) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed NDA for F351 (hydronidone) for CHB-induced liver fibrosis accepted by China's